genomics « Science and Enterprise

In one of its first actions, the Biden administration rejoined the United States in the World Health Organization,… https://t.co/gpHTTr70DP
about 13 hours ago
New post on Science and Enterprise: U.S. Rejoins WHO, Participates in Int’l Vaccine Project https://t.co/bBUZr5UzSg #Science #Business
about 13 hours ago
A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower ris… https://t.co/EPYrP8wElE
about 17 hours ago
New post on Science and Enterprise: Antibodies Prevent Covid-19 Symptoms in Long-Term Care https://t.co/sePqojZMVd #Science #Business
about 17 hours ago
Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
about 1 day ago

Crispr Heart Disease Biotech Raises $94M in New Funds

By Alan, on January 19th, 2021%

A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds

Biotech Licenses mRNA Technology for Aging

By Alan, on January 13th, 2021%

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Drug Maker Gains Access to Hidden Protein Immunotherapies

By Alan, on January 12th, 2021%

Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies

Moderna Developing Flu, HIV, Nipah Vaccines

By Alan, on January 11th, 2021%

Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines

Vaccine Shown Active Against New Covid-19 Variants

By Alan, on January 8th, 2021%

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

CureVac, Bayer Partner on Covid-19 Vaccine Supply

By Alan, on January 7th, 2021%

Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine. . . . → Read More: CureVac, Bayer Partner on Covid-19 Vaccine Supply

Synthetic Biology Company Raises $105M in New Funds

By Alan, on January 7th, 2021%

A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round. . . . → Read More: Synthetic Biology Company Raises $105M in New Funds

FDA Issues Precision Genomic Drug Guidance

By Alan, on January 4th, 2021%

The U.S. Food and Drug Administration issued draft administrative and procedural guidelines for genetic disorders treated with precise gene therapies. . . . → Read More: FDA Issues Precision Genomic Drug Guidance

Trial OKed for Rare Disease Gene Therapy

By Alan, on January 4th, 2021%

A start-up biotech company says it received clearance from the Food and Drug Administration to begin a clinical trial of its gene therapy for Krabbe disease. . . . → Read More: Trial OKed for Rare Disease Gene Therapy

Device-Aided Covid-19 Vaccine Invokes Immune Response

By Alan, on December 24th, 2020%

Results from an early clinical trial show a Covid-19 vaccine using an electronic device to boost uptake in cells is safe and generates an immune-system response. . . . → Read More: Device-Aided Covid-19 Vaccine Invokes Immune Response

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise